S&P 500   3,960.30 (-0.08%)
DOW   33,691.70 (-0.27%)
QQQ   284.26 (+0.14%)
AAPL   144.26 (+1.13%)
MSFT   247.00 (-0.16%)
META   116.82 (+1.29%)
GOOGL   93.47 (-0.26%)
AMZN   89.61 (-0.82%)
TSLA   181.60 (+4.70%)
NVDA   173.31 (+0.94%)
NIO   12.85 (-4.18%)
BABA   92.32 (-1.96%)
AMD   69.67 (-1.14%)
T   19.19 (+0.37%)
MU   55.54 (+0.62%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.25 (-1.65%)
DIS   94.11 (+1.69%)
AMC   5.83 (-3.95%)
PYPL   74.20 (-0.03%)
PFE   51.89 (+0.21%)
NFLX   324.41 (+4.56%)
S&P 500   3,960.30 (-0.08%)
DOW   33,691.70 (-0.27%)
QQQ   284.26 (+0.14%)
AAPL   144.26 (+1.13%)
MSFT   247.00 (-0.16%)
META   116.82 (+1.29%)
GOOGL   93.47 (-0.26%)
AMZN   89.61 (-0.82%)
TSLA   181.60 (+4.70%)
NVDA   173.31 (+0.94%)
NIO   12.85 (-4.18%)
BABA   92.32 (-1.96%)
AMD   69.67 (-1.14%)
T   19.19 (+0.37%)
MU   55.54 (+0.62%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.25 (-1.65%)
DIS   94.11 (+1.69%)
AMC   5.83 (-3.95%)
PYPL   74.20 (-0.03%)
PFE   51.89 (+0.21%)
NFLX   324.41 (+4.56%)
S&P 500   3,960.30 (-0.08%)
DOW   33,691.70 (-0.27%)
QQQ   284.26 (+0.14%)
AAPL   144.26 (+1.13%)
MSFT   247.00 (-0.16%)
META   116.82 (+1.29%)
GOOGL   93.47 (-0.26%)
AMZN   89.61 (-0.82%)
TSLA   181.60 (+4.70%)
NVDA   173.31 (+0.94%)
NIO   12.85 (-4.18%)
BABA   92.32 (-1.96%)
AMD   69.67 (-1.14%)
T   19.19 (+0.37%)
MU   55.54 (+0.62%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.25 (-1.65%)
DIS   94.11 (+1.69%)
AMC   5.83 (-3.95%)
PYPL   74.20 (-0.03%)
PFE   51.89 (+0.21%)
NFLX   324.41 (+4.56%)
S&P 500   3,960.30 (-0.08%)
DOW   33,691.70 (-0.27%)
QQQ   284.26 (+0.14%)
AAPL   144.26 (+1.13%)
MSFT   247.00 (-0.16%)
META   116.82 (+1.29%)
GOOGL   93.47 (-0.26%)
AMZN   89.61 (-0.82%)
TSLA   181.60 (+4.70%)
NVDA   173.31 (+0.94%)
NIO   12.85 (-4.18%)
BABA   92.32 (-1.96%)
AMD   69.67 (-1.14%)
T   19.19 (+0.37%)
MU   55.54 (+0.62%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.25 (-1.65%)
DIS   94.11 (+1.69%)
AMC   5.83 (-3.95%)
PYPL   74.20 (-0.03%)
PFE   51.89 (+0.21%)
NFLX   324.41 (+4.56%)
NASDAQ:HZNP

Horizon Therapeutics Public - HZNP Stock Forecast, Price & News

$97.22
+0.31 (+0.32%)
(As of 12/9/2022 02:27 PM ET)
Add
Compare
Today's Range
$96.58
▼
$97.99
50-Day Range
$61.58
▼
$104.85
52-Week Range
$57.84
▼
$117.49
Volume
82,218 shs
Average Volume
3.07 million shs
Market Capitalization
$22.03 billion
P/E Ratio
39.84
Dividend Yield
N/A
Price Target
$109.20

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
12.3% Upside
$109.20 Price Target
Short Interest
Healthy
3.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.35mentions of Horizon Therapeutics Public in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
29.83%
From $4.19 to $5.44 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

95th out of 1,022 stocks

Pharmaceutical Preparations Industry

37th out of 499 stocks

See Top Rated MarketRank™ Stocks Here
HZNP stock logo

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Stock News Headlines

December 8, 2022 | americanbankingnews.com
Piper Sandler Boosts Horizon Therapeutics Public (NASDAQ:HZNP) Price Target to $110.00
December 7, 2022 | americanbankingnews.com
FY2023 Earnings Forecast for Horizon Therapeutics Public Limited (NASDAQ:HZNP) Issued By Jefferies Financial Group
December 9, 2022 | Investing Trends (Ad)
The Critical Minerals Race: U.S. v China
The U.S. is dangerously lacking in critical minerals such as cobalt, lithium, and rare earths needed to maintain our national security. China is aggressively locking up mines and production. But the U.S. is about to strike back with a forceful plan of action to increase domestic production.
December 4, 2022 | americanbankingnews.com
Horizon Therapeutics Public (NASDAQ:HZNP) PT Raised to $125.00 at Jefferies Financial Group
December 3, 2022 | finance.yahoo.com
Are Investors Undervaluing Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) By 50%?
December 3, 2022 | americanbankingnews.com
Analysts Set Horizon Therapeutics Public Limited (NASDAQ:HZNP) PT at $105.00
December 1, 2022 | americanbankingnews.com
Stock Traders Purchase Large Volume of Put Options on Horizon Therapeutics Public (NASDAQ:HZNP)
November 30, 2022 | msn.com
$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
December 9, 2022 | Investing Trends (Ad)
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
November 30, 2022 | msn.com
Horizon Therapeutics in separate sale talks with Amgen, Sanofi and J&J
November 29, 2022 | msn.com
Drug company Horizon Therapeutics confirms it is in talks with potential suitors
November 23, 2022 | finance.yahoo.com
Horizon Therapeutics (HZNP) is a Top-Ranked Value Stock: Should You Buy?
November 16, 2022 | finance.yahoo.com
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
November 16, 2022 | finance.yahoo.com
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
November 10, 2022 | finance.yahoo.com
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
November 9, 2022 | finance.yahoo.com
Why Horizon Therapeutics Public Limited Company (HZNP) Declined in the Third Quarter?
November 8, 2022 | finance.yahoo.com
Horizon Therapeutics Third Quarter 2022 Earnings: Beats Expectations
November 8, 2022 | finance.yahoo.com
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
November 5, 2022 | finance.yahoo.com
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
November 2, 2022 | benzinga.com
This Is What Whales Are Betting On Horizon Therapeutics
November 2, 2022 | finance.yahoo.com
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
November 1, 2022 | finance.yahoo.com
Horizon Therapeutics plc Named to the Seramount Inclusion Index
October 27, 2022 | finance.yahoo.com
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
October 26, 2022 | finance.yahoo.com
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
October 22, 2022 | finance.yahoo.com
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
October 13, 2022 | finance.yahoo.com
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
October 12, 2022 | finance.yahoo.com
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings
11/03/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
CIK
1492426
Web
www.horizontherapeutics.com
Phone
(531) 772-2100
Fax
224-383-3001
Employees
1,890
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$109.20
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+12.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.44
Trailing P/E Ratio
39.84
Forward P/E Ratio
23.20
P/E Growth
1.92
Net Income
$534.49 million
Net Margins
15.51%
Pretax Margin
15.77%
Return on Equity
24.59%
Return on Assets
13.56%

Debt

Debt-to-Equity Ratio
0.51
Current Ratio
3.96
Quick Ratio
3.74

Sales & Book Value

Annual Sales
$3.23 billion
Price / Sales
6.83
Cash Flow
$6.50 per share
Price / Cash Flow
14.95
Book Value
$20.60 per share
Price / Book
4.72

Miscellaneous

Outstanding Shares
226,620,000
Free Float
220,955,000
Market Cap
$22.03 billion
Optionable
Optionable
Beta
1.23

Social Links


Key Executives

  • Mr. Timothy P. WalbertMr. Timothy P. Walbert (Age 55)
    Chairman, Pres & CEO
    Comp: $5.54M
  • Dr. Jeffrey W. Sherman F.A.C.P. (Age 67)
    FACP, M.D., Exec. VP & Chief Medical Officer
    Comp: $1.65M
  • Mr. Paul W. HoelscherMr. Paul W. Hoelscher (Age 57)
    Advisor
    Comp: $2.07M
  • Mr. Andy PasternakMr. Andy Pasternak (Age 51)
    Exec. VP & Chief Strategy Officer
    Comp: $1.67M
  • Mr. Aaron L. Cox (Age 39)
    Exec. VP of Fin. & CFO
  • Mr. Miles W. McHughMr. Miles W. McHugh (Age 57)
    Chief Accounting Officer & Sr. VP
  • Ms. Tina E. Ventura
    Sr. VP & Chief Investor Relations Officer
  • Mr. Sean M. Clayton J.D.Mr. Sean M. Clayton J.D. (Age 43)
    Exec. VP & Gen. Counsel
  • Mr. Geoffrey M. CurtisMr. Geoffrey M. Curtis (Age 47)
    Exec. VP of Corp. Affairs & Chief Communications Officer
  • Ms. Jane Gonnerman
    Group VP of Corp. Devel., Chief of Staff & Office of the CEO

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HZNP shares.
View HZNP analyst ratings or view top-rated stocks.

What is Horizon Therapeutics Public's stock price forecast for 2023?

9 brokerages have issued 1-year price targets for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they expect the company's stock price to reach $109.20 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.

How have HZNP shares performed in 2022?

Horizon Therapeutics Public's stock was trading at $107.76 on January 1st, 2022. Since then, HZNP stock has decreased by 9.6% and is now trading at $97.42.
View the best growth stocks for 2022 here.

When is Horizon Therapeutics Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our HZNP earnings forecast.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported $1.75 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.21. The biopharmaceutical company earned $1.04 billion during the quarter, compared to analyst estimates of $979.49 million. Horizon Therapeutics Public had a net margin of 15.51% and a trailing twelve-month return on equity of 24.59%. The company's revenue was up 62.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.74 earnings per share.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.59 billion-$3.61 billion, compared to the consensus revenue estimate of $3.56 billion.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.39%), BlackRock Inc. (6.89%), Nuveen Asset Management LLC (3.07%), Paulson & CO. Inc. (2.69%), State Street Corp (2.53%) and Barclays PLC (1.67%). Insiders that own company stock include Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $97.42.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $22.08 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $2.44 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

The company employs 1,890 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..
Read More
How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 12/9/2022 by MarketBeat.com Staff